Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Berry

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662D F Hayes, H Yamauchi, G Broadwater, et al.
Journal of the National Cancer Institute|August 27, 1998
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group BD R Budman, D A Berry, C T Cirrincione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapyL N Harris, V Liotcheva, G Broadwater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140H L Parnes, C Cirrincione, J Aisner, et al.
The Journal of Biological Chemistry|May 10, 2000
The oxidative DNA lesion 8,5'-(S)-cyclo-2'-deoxyadenosine is repaired by the nucleotide excision repair pathway and blocks gene expression in mammalian cellsP J Brooks, D S Wise, D A Berry, et al.
Electrophoresis|January 1, 1996
Different electrophoretic techniques produce conflicting data in the analysis of myocardial samples from dilated cardiomyopathy patients: protein levels do not necessarily reflect mRNA levelsC G dos Remedios, D A Berry, L K Carter, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignanciesA M Hussein, W P Petros, M Ross, et al.
Breast Cancer Research and Treatment|November 21, 2016
Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)Rachel A Freedman, D K Seisler, J C Foster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2022
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trialsM Marczyk, A Mrukwa, C Yau, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662D F Hayes, H Yamauchi, G Broadwater, et al.
Journal of the National Cancer Institute|August 27, 1998
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group BD R Budman, D A Berry, C T Cirrincione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapyL N Harris, V Liotcheva, G Broadwater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140H L Parnes, C Cirrincione, J Aisner, et al.
The Journal of Biological Chemistry|May 10, 2000
The oxidative DNA lesion 8,5'-(S)-cyclo-2'-deoxyadenosine is repaired by the nucleotide excision repair pathway and blocks gene expression in mammalian cellsP J Brooks, D S Wise, D A Berry, et al.
Electrophoresis|January 1, 1996
Different electrophoretic techniques produce conflicting data in the analysis of myocardial samples from dilated cardiomyopathy patients: protein levels do not necessarily reflect mRNA levelsC G dos Remedios, D A Berry, L K Carter, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignanciesA M Hussein, W P Petros, M Ross, et al.
Breast Cancer Research and Treatment|November 21, 2016
Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)Rachel A Freedman, D K Seisler, J C Foster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2022
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trialsM Marczyk, A Mrukwa, C Yau, et al.
Pageof 9